person · Reporting owner

Mates Sharon

Disclosed activity across 3 companies

Tapewire entity: 50018
SEC CIK: 0001585699

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Benitec Biopharma Inc.BNTC · Entity 5596	Director	January 22, 2026	January 26, 2026
Seaport Therapeutics, Inc.SPTX · Entity 4799	Director	April 30, 2026	May 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Benitec Biopharma Inc.

Report date January 22, 2026 · Filed January 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.83 · Expires 2036-01-22	Direct	31,500	Reported balance After 2026-01-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-22 · Grant · Acquired 31,500 · Balance 31,500 F1: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Seaport Therapeutics, Inc.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-04-29	Direct	49,033	Reported balance After 2026-04-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-30 · Grant · Acquired 49,033 · Balance 49,033 F1: 1/3rd of the shares underlying this option shall vest and become exercisable on April 30, 2027, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/3rd of the shares underlying this option shall vest and become exercisable on April 30, 2027, with the remaining shares vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Intra-Cellular Therapies, Inc.

Report date April 02, 2025 · Filed April 02, 2025

Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-04-02 transaction · row 1 1 source row Row 1 · 2025-04-02 · Disposition to issuer · Disposed 945,235 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
Common StockSEC Table I · non-derivative	IndirectBy the Sharon Mates Family Foundation	0	Reported balance After 2025-04-02 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-04-02 · Disposition to issuer · Disposed 190,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3: These shares are held by the Sharon Mates Family Foundation (the "Foundation"). The reporting person disclaims beneficial ownership of the shares held by the Foundation except to the extent of her pecuniary interest therein, if any.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.63 · Expires 2026-01-03	Direct	0	Reported balance After 2025-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-04-02 · Disposition to issuer · Disposed 86,003 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.73 · Expires 2027-01-02	Direct	0	Reported balance After 2025-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-04-02 · Disposition to issuer · Disposed 135,399 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.47 · Expires 2028-01-02	Direct	0	Reported balance After 2025-04-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-04-02 · Disposition to issuer · Disposed 138,473 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.94 · Expires 2030-02-17	Direct	0	Reported balance After 2025-04-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-04-02 · Disposition to issuer · Disposed 66,886 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.89 · Expires 2031-02-22	Direct	0	Reported balance After 2025-04-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-04-02 · Disposition to issuer · Disposed 53,471 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.73 · Expires 2032-03-09	Direct	0	Reported balance After 2025-04-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-04-02 · Disposition to issuer · Disposed 50,167 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-04-02 · Disposition to issuer · Disposed 40,713 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-04-02 · Disposition to issuer · Disposed 69,940 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-04-02 · Disposition to issuer · Disposed 121,212 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	40,712	Reported balance After 2025-04-02 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-04-02 · Grant · Acquired 40,712 · Balance 40,712 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-04-02 · Disposition to issuer · Disposed 40,712 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	34,970	Reported balance After 2025-04-02 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2025-04-02 · Grant · Acquired 34,970 · Balance 34,970 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-02 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2025-04-02 · Disposition to issuer · Disposed 34,970 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable. F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration. F8: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F3: These shares are held by the Sharon Mates Family Foundation (the "Foundation"). The reporting person disclaims beneficial ownership of the shares held by the Foundation except to the extent of her pecuniary interest therein, if any.

F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.

F6: Each restricted stock unit (each, a "Company RSU") and each performance-based restricted stock unit (each, a "Company PRSU") represented a contingent right to receive one Company Share for each Company RSU and Company PRSU, as applicable.

F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F8: Not applicable.

F9: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company PRSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company PRSU immediately prior to the Effective Time determined by treating all applicable performance measures as satisfied at the target level of performance and (ii) the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 08, 2022 Filed Jan 11, 2022 20:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	41,896	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002984 · doc4.xml · derivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F7 · derivative.exercise_date: On January 8, 2019, the reporting person was granted 125,687 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On January 8, 2019, the reporting person was granted 125,687 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 08, 2022 Filed Jan 11, 2022 20:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	41,896	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-002984 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
October 18, 2021 Filed Oct 18, 2021 18:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	8,192	$40.00	$327,680.00	Disclosure SEC source: 0001209191-21-060741 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,094,467 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
October 15, 2021 Filed Oct 18, 2021 18:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	1,075	$0.00 Strike: $2.84	$0.00	Disclosure SEC source: 0001209191-21-060741 · doc4.xml · derivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,925 Underlying: Common Stock · 1,075 shares Expires 2022-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
October 15, 2021 Filed Oct 18, 2021 18:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	1,075	$2.84	$3,053.00	Disclosure SEC source: 0001209191-21-060741 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 15, 2021 Filed Oct 18, 2021 18:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	40,392	$40.00	$1,615,680.00	Disclosure SEC source: 0001209191-21-060741 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101,584 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. Read SEC document
October 14, 2021 Filed Oct 18, 2021 18:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	1,416	$40.00	$56,640.00	Disclosure SEC source: 0001209191-21-060741 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141,976 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021. Read SEC document
August 23, 2021 Filed Aug 24, 2021 16:06 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $2.84	$0.00	Disclosure SEC source: 0001209191-21-053102 · doc4.xml · derivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2022-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
August 23, 2021 Filed Aug 24, 2021 16:06 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	10,000	$2.84	$28,400.00	Disclosure SEC source: 0001209191-21-053102 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2021 Filed Feb 25, 2021 16:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantRestricted Stock Units · Derivative	67,769	$0.00	$0.00	Disclosure SEC source: 0001209191-21-014279 · doc4.xml · derivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,769 Underlying: Common Stock · 67,769 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 23, 2021 Filed Feb 25, 2021 16:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	53,471	$0.00 Strike: $36.89	$0.00	Disclosure SEC source: 0001209191-21-014279 · doc4.xml · derivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,471 Underlying: Common Stock · 53,471 shares Expires 2031-02-22 F1 · derivative.exercise_date: On February 23, 2021, the reporting person was granted options to purchase 53,471 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 19, 2021 Filed Feb 22, 2021 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	3,100	$38.91	$120,621.00	Disclosure SEC source: 0001209191-21-012949 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,392 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 to $38.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 19, 2021 Filed Feb 22, 2021 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	24,747	$39.27	$971,814.69	Disclosure SEC source: 0001209191-21-012949 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,492 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
February 18, 2021 Filed Feb 22, 2021 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	27,847	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012949 · doc4.xml · derivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,695 Underlying: Common Stock · 27,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 18, 2021 Filed Feb 22, 2021 20:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	27,847	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-012949 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 11, 2021 Filed Jan 12, 2021 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	4,585	$31.64	$145,069.40	Disclosure SEC source: 0001209191-21-003312 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,392 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 to $31.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 11, 2021 Filed Jan 12, 2021 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	37,311	$32.06	$1,196,190.66	Disclosure SEC source: 0001209191-21-003312 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,977 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $32.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 08, 2021 Filed Jan 12, 2021 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	41,896	$0.00	$0.00	Disclosure SEC source: 0001209191-21-003312 · doc4.xml · derivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,896 Underlying: Common Stock · 41,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: On January 8, 2019, the reporting person was granted 125,687 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On January 8, 2019, the reporting person was granted 125,687 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 08, 2021 Filed Jan 12, 2021 19:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	41,896	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-003312 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 04, 2021 Filed Jan 5, 2021 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	2,800	$30.94	$86,632.00	Disclosure SEC source: 0001209191-21-001516 · doc4.xml · nonDerivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,392 F5 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.84 to $31.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 04, 2021 Filed Jan 5, 2021 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	11,200	$31.39	$351,568.00	Disclosure SEC source: 0001209191-21-001516 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,192 F5 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.11 to $32.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 04, 2021 Filed Jan 5, 2021 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	6,428	$30.94	$198,882.32	Disclosure SEC source: 0001209191-21-001516 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147,392 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.84 to $31.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 04, 2021 Filed Jan 5, 2021 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	27,913	$31.39	$876,189.07	Disclosure SEC source: 0001209191-21-001516 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,153,820 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.10 to $32.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 03, 2021 Filed Jan 5, 2021 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	34,341	$0.00	$0.00	Disclosure SEC source: 0001209191-21-001516 · doc4.xml · derivative · entry 6 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F8 · derivative.exercise_date: On January 3, 2018, the reporting person was granted 103,021 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On January 3, 2018, the reporting person was granted 103,021 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 03, 2021 Filed Jan 5, 2021 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	34,341	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-001516 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
December 18, 2020 Filed Dec 21, 2020 16:03 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	34,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001209191-20-064616 · doc4.xml · derivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2020-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
December 18, 2020 Filed Dec 21, 2020 16:03 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	34,000	$2.74	$93,160.00	Disclosure SEC source: 0001209191-20-064616 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 10, 2020 Filed Nov 12, 2020 17:51 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	19,131	$26.91	$514,815.21	Disclosure SEC source: 0001209191-20-058082 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,392 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.60 to $27.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
November 10, 2020 Filed Nov 12, 2020 17:51 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	30,869	$25.99	$802,285.31	Disclosure SEC source: 0001209191-20-058082 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,132,523 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.59 to $26.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
November 04, 2020 Filed Nov 6, 2020 18:00 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	50,000	$25.00	$1,250,000.00	Disclosure SEC source: 0001209191-20-057347 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163,392 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 19, 2020. Read SEC document
February 18, 2020 Filed Feb 20, 2020 19:42 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantRestricted Stock Units · Derivative	83,542	$0.00	$0.00	Disclosure SEC source: 0001209191-20-011318 · doc4.xml · derivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,542 Underlying: Common Stock · 83,542 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On February 18, 2020, the reporting person was granted 83,542 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 18, 2020 Filed Feb 20, 2020 19:42 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	66,886	$0.00 Strike: $23.94	$0.00	Disclosure SEC source: 0001209191-20-011318 · doc4.xml · derivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,886 Underlying: Common Stock · 66,886 shares Expires 2030-02-17 F1 · derivative.exercise_date: On February 18, 2020, the reporting person was granted options to purchase 66,886 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 24, 2020 Filed Jan 28, 2020 21:28 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	OtherCommon Stock	9,323	$23.61	$220,116.03	Disclosure SEC source: 0001209191-20-005265 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,213,392 F2 · kind: Represents withholding of shares by the issuer for payment of the reporting person's tax liability upon the vesting of performance stock units. Read SEC document
January 24, 2020 Filed Jan 28, 2020 21:28 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	18,008	$0.00	$0.00	Disclosure SEC source: 0001209191-20-005265 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,715 F1 · kind: Represents shares issued upon the vesting of performance stock units. Read SEC document
January 09, 2020 Filed Jan 10, 2020 21:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	41,895	$26.16	$1,095,973.20	Disclosure SEC source: 0001209191-20-003146 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,204,707 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.87 to $26.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 08, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	16,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · derivative · entry 8 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 16,000 shares Expires 2020-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
January 08, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	44,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · derivative · entry 7 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2020-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
January 08, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	41,895	$0.00	$0.00	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · derivative · entry 6 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,792 Underlying: Common Stock · 41,895 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: On January 8, 2019, the reporting person was granted 125,687 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On January 8, 2019, the reporting person was granted 125,687 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 08, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	16,000	$2.74	$43,840.00	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · nonDerivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,246,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 08, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	44,000	$2.74	$120,560.00	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 08, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	41,895	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · nonDerivative · entry 3 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,186,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 06, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	37,659	$30.39	$1,144,457.01	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · nonDerivative · entry 2 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,144,707 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 06, 2020 Filed Jan 8, 2020 21:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	7,939	$29.78	$236,423.42	Disclosure SEC source: 0001209191-20-002646 · doc4.xml · nonDerivative · entry 1 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,182,366 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.61 to $29.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 03, 2020 Filed Jan 3, 2020 21:14 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	34,340	$0.00	$0.00	Disclosure SEC source: 0001209191-20-001465 · doc4.xml · derivative · entry 11 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,341 Underlying: Common Stock · 34,340 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F10 · derivative.exercise_date: On January 3, 2018, the reporting person was granted 103,021 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F10 · derivative.expiration_date: On January 3, 2018, the reporting person was granted 103,021 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 03, 2020 Filed Jan 3, 2020 21:14 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionRestricted Stock Units · Derivative	11,258	$0.00	$0.00	Disclosure SEC source: 0001209191-20-001465 · doc4.xml · derivative · entry 10 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F9 · derivative.exercise_date: On January 3, 2017, the reporting person was granted 33,773 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F9 · derivative.expiration_date: On January 3, 2017, the reporting person was granted 33,773 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 03, 2020 Filed Jan 3, 2020 21:14 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	34,340	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-001465 · doc4.xml · nonDerivative · entry 8 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,190,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 03, 2020 Filed Jan 3, 2020 21:14 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	11,258	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-001465 · doc4.xml · nonDerivative · entry 7 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:14 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	56	$34.30	$1,920.80	Disclosure SEC source: 0001209191-20-001465 · doc4.xml · nonDerivative · entry 6 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,144,707 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:14 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	3,000	$33.25	$99,750.00	Disclosure SEC source: 0001209191-20-001465 · doc4.xml · nonDerivative · entry 5 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,144,763 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:14 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	10,722	$32.43	$347,714.46	Disclosure SEC source: 0001209191-20-001465 · doc4.xml · nonDerivative · entry 4 Mates Sharon · CIK 0001585699 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147,763 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 19, 2019. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of performance stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.